Feature|Articles|April 8, 2025

Baseline 68Ga-PSMA-11 PET/CT parameters can predict response to 177Lu-PSMA-617

Author(s)Phillip Kuo, MD, PhD, Hannah Clarke

"For every 1 unit increase in whole body tumor SUVmean, there was a 12% decrease in the risk of an rPFS event and a 10% decrease in the risk of death," says Phillip H. Kuo, MD, PhD, FACR.

In this interview, Phillip H. Kuo, MD, PhD, FACR, shares key findings and takeaways from the study, “Quantitative ⁶⁸Ga-PSMA-11 PET and clinical outcomes in metastatic castration-resistant prostate cancer following ¹⁷⁷Lu-PSMA-617 (VISION trial),”¹ for which he served as the lead author. Kuo is a professor of radiology, section chief of nuclear medicine, and director of theranostics for the department of radiology at City of Hope National Medical Center in Duarte, California.